Editas Medicine, Inc.
Editas Medicine, Inc. (EDIT) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · EDIT · as of Jun 8, 2026
Key Statistics
Explore Editas Medicine, Inc. Data
edit stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 25 · Buy rate: 56.0%
The EDIT analyst consensus is Buy, based on ratings from 25 Wall Street analysts over the past 3 months. The average 12-month price target is $5.00, representing +89.04% upside from the current price of $2.65.
Competitors & Peers
edit competitorsEDIT
ALLO
AVIR
CABA
CAPR
IMMPStock Performance
Full HistoryAbout Editas Medicine, Inc.
Editas Medicine, Inc. is a leading biotechnology firm focused on clinical-stage genome editing, with a primary mission to pioneer groundbreaking genetic therapies designed to address a wide array of s…
what is editas medicine, inc. · edit stock overview · editas medicine, inc. company profile · who is editas medicine, inc. ceo · edit NASDAQ · editas medicine, inc. headquarters · editas medicine, inc. business segments
About Stock Overview & Key Data
Editas Medicine, Inc. (EDIT) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Feb 3, 2016. As of the latest trading session, EDIT stock price is $2.65, with a market capitalization of $258.9M. The stock has returned +37.05% over the past 12 months and +29.02% year-to-date.
According to 25 Wall Street analysts, the consensus rating for Editas Medicine, Inc. stock is Buy, with an average 12-month price target of $5.00. In fiscal year 2025, Editas Medicine, Inc. reported revenue of $40.5M and net income of -$160.1M. For detailed data — including Editas Medicine, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Editas Medicine, Inc. (EDIT) stock price is $2.65. The stock is traded on NASDAQ under the ticker symbol EDIT. The 52-week range is $1.66 – $4.54.